Skip to main content

Table 2 Laboratory and clinical characteristics of patients with and without pathological levels of fecal elastase

From: Exocrine pancreatic function is preserved in systemic sclerosis

 

ALT (U/L)

AST (U/L)

GGT (U/L)

ALP (U/L)

Pancreatic amylase (U/L)

Calcium (mmol/l)

Magnesium (mmol/l)

Albumin (g/l)

Prealbumin (g/l)

Vitamin D3 (nmol/l)

Disease duration (years)

Age (years)

ACA (n)

ATA (n)

ARA (n)

FE ≤ 200 μg/g (n = 6)

25 (16–41)

29 (22, 40)

55 (22, 156)

71 (71,881.2)

24 (22, 32)

2.4 (2.3, 2.5)

0.93 (0.77, 1.1)

40 (37, 42)

0.33 (0.19, 0.36)

48 (29, 65)

5 (1, 15)

70 (57, 76)

1

1

1

FE > 200 μg/g (n = 106)

19 (14, 24)

24 (21, 29)

25 (17, 0.46)

71 (52, 81)

25 (18, 0.38)

2.3 (2.3, 2.4)

0.82 (0.77, 0.86)

39 (36, 41)

0.25 (0.2, 0.3)

70 (45, 78)

7(3, 15)

60 (61, 69)

38

19

9

  1. Systemic sclerosis patients with pathological FE testing did not differ compared to other patients with regard to laboratory markers of liver function and malnutrition, disease duration, age, and antibody profile. p > 0.05 for all variables when comparing patients with FE ≤ 200 μg/g to patients with FE > 200 μg/g. Values are given as median (interquartile range)
  2. FE fecal elastase, ALT alanin aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, ALP alkaline phosphatase, ACA anti-centromere antibodies, ATA anti-topoisomerase antibodies, ARA anti-RNA polymerase III antibodies